Abstract
In the present study, cisplatin (cDDP) and carboplatin (CBDCA) were combined in different in vitro and in vivo assays to determine whether combined cDDP and CBDCA treatment would eventually lead to a better antitumor response. Co-incubation of CC531 cells with cDDP and CBDCA led to higher intracellular Pt concentrations (30.5±3.4 ng Pt/106 cells) than did cDDP (16.9±9.4 ng Pt/106 cells) or CBDCA (1.28±0.72 ng Pt/106 cells) incubation alone. In survival assays an additive cell kill was seen after combined treatment with cDDP and CBDCA. DNA binding experiments using isolated salmon-sperm DNA exposed to the drugs separately or in combination were in agreement with the survival studies (for cDDP a binding of 12.42 μg Pt/mg DNA; for CBDCA, 0.49 μg Pt/mg DNA at 76 h). Toxicity studies in rats treated with cDDP plus CBDCA required a dose reduction for cDDP amounting to 20% of the MTD, whereas the CBDCA dose could be maintained. Pharmacokinetics studies showed higher AUCs andt 1/2β in plasma as well as the peritoneal cavity after combined treatment with cDDP and CBDCA (both given i.p.) or following cDDP given i.p. and CBDCA given i.v. Pt concentrations in peritoneal tumors corresponded with these observations, with higher Pt concentrations following combined treatment than after single-agent injection. In addition, combined adminstration of cDDP i.p. and CBDCA i.v. led to higher Pt concentrations in peritoneal tumors than did administration of both drugs i.p. (3.93±0.9 vs 2.76±0.2 mg Pt/g tissue). The higher Pt concentrations in the peritoneal tumors after combined treatment was associated with a significantly better antitumor response in comparison with that observed after single-agent treatment (a growth delay of 30.2±5.6 days for cDDP i.p. plus CBDCA i.v. vs 16.1±5.4 days for cDDP alone and 10.8±4.2 days for CBDCA alone).
Similar content being viewed by others
References
Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Frank CR (1989) Comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28: 57
Brenner DE (1987) Intraperitoneal chemotherapy, a review. J Clin Oncol 4: 1135
Calvert AH, Harland SJ, Newell DR, Jones AC, McElwain TJ, Raju S, Wilshaw E, Smith IE, Baker JM, Peckman MJ, Harrap KR (1982) Early clinical studies withcis-diammine-1,1-cyclobutanedicarboxylatoplatinum II. Cancer. Chemother Pharmacol 9: 140
Canetta R, Bragman M, Smaldone L, Rozencweig M (1988) Carboplatin: current status and further prospects. Cancer Treat Rev 15: 17
Colombo N, Speyer, J, Wernz, J, Beckman EM, Beller U, Meyers M, Canette R, Muggia FM (1987) Phase I–II study of intraperitoneal (ip) CBDCA in patients with ovarian cancer. Proc Am Soc Clin Oncol 6: 113
Curt GA, Grygiel JJ, Gorden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins RM (1983) A phase I and pharmacokinetics study of diammine-cyclobutanedicarboxylatoplatinum (NSC 241240). Cancer Res, 43: 4470
Dedrick RL (1985) Theroretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12: 1
Dedrick RL, Myers CE, Bungay PM, De Vita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1
DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI (1986) Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18: 235
Elferink F, Vijgh van der WJF, Klein I, Vermorken JB, Gall HE, Pinedo HM (1987) Pharmacokinetics of diammine(1,1-cyclobutanedicarboxylato)-platinum(II) (carboplatin) after intravenous administration. Cancer Treat Rep 71: 1231
Elferink F, Vijgh WJF van der, Klein I, Bokkel Huinink WW ten, Dubbelman R, McVie JG (1988) Pharmacokinetics of diammine (1,1,-cyclobutanedicarboxylato)-platinum(II) (carboplatin) after intraperitoneal administration. Cancer Chemother Pharmacol 21: 57
Fichtinger-Schepman AMJ, Veer JL van der, Hartog JHJ den, Lohman PHM, Reedijk J (1985) Adducts of the antitumor drugcis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707
Foster BJ, Harding BJ, Wolpert-de Filippes MK, Rubinstein LY, Clagett-Carr K, Leyland-Jones B (1990) A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. Cancer Chemother Pharmacol 25: 395
George M, Kerbrat P, Heron JF et al (1988) Phase I–II study of high-dose carboplatin at first line chemotherapy of extensive epithelial ovarian cancer Proc Am Soc Clin Oncol 7: 140
Graeff A de, Slebos RJC, Rodenhuis S (1988) Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol, 22: 325
Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, Horton MC, McVey L, Morris J, Weiss RJ (1990) A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 8: 137
Knox RJ, Friedlos F, Lydall DA, Robers JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence thatcis-diamminedichloroplatinum(II) andcis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics in their interaction with DNA. Cancer Res 46: 1972
Los G, McVie JG (1990) Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 26: 775
Los G, Mutsaers PHA, Vijgh WJF van der, Baldew GS, Graaf PW de, McVie JG (1989) Direct diffusion ofcis-diamminedichloroplatinum(II) in intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380
Los G, Verdegaal EME, Mutsaers PHA, McVie JG (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28: 159
Los G, Verdegaal E, Noteborn HPJM, Ruevekamp M, Graeff PW de, Meester EW, Bokkel Huinink D ten, McVie JG (1991) Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol 42: 357
Los G, Smals OAG, Vugt M van, Vlist M van der, Engelse L den, McVie JG, Pinedo HM (1992) A rationale for carboplatin treatment and regional hyperthermia in cancers restricted to the peritoneal cavity in the rat. Cancer Res 52: 1252
Lum BL, DeGregorio MW, Holleran WM, DaRoza R, Brown M, Schiffman R, Jacobs CD, Lewis RL, Halsey J, Scudder SA, Sikic BI (1986) The clinical pharmacology of intraperitoneal carboplatin: a phase I/II study of the Northern California Oncology Group. Proc Am Soc Clin Oncol 5: 50
Lund B, Hansen M, Hansen OP, Hansen HH (1990) Combined high-dose carbo-and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 8: 1226
Markman M (1991) Intraperitoneal chemotherapy. Semin Oncol 18: 248
McVie JG, Bokkel Huinink WW ten, Dubbelman R, Franklin H, Vijgh WJF van der, Klein I (1985) Phase I study and pharmacokinetics of intraperitoneal carboplatin. Cancer Treat Rev 12: 35
Neijt JP, Burg MEL van der, Vriesekoop R, Lindert AMC van, Lent M van, Bokkel Huinink WW ten, Oosterom AT van, Hamerlynk JVTH, Houwelingen JC van, Pinedo HM (1984) Randomized trials comparing two combinations of chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet II: 594
Neijt JP, Bokkel Huinink WW ten, Burg MEL van der, et al (1987) Randomized trial comparing two combinations chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157
Omura GA, Bundy BN, Berek JS, et al (1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian cancer carcinoma: a Gynecologic Oncology Group study J Clin Oncol 7: 457
Ozols RF (1985) Pharmacologic reversal of drug resistance in ovarian cancer. Semin Oncol 12: 7
Ozols RF, Young RC (1985) High dose cisplatin treatment in ovarian cancer. Semin Oncol 12: 21
Ozols RF, Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: 222
Ozols RF, Ostchega Y, Myers CE, Young RC (1985) High-dose cisplatin in hypertonic saline in refractory ovarian cancer patients. J Clin Oncol 3: 1246
Ozols RF, Hamilton TC, Hoskins WJ, Bast RCJ, Young RC (1991) Summary of Symposium: biology and therapy of ovarian cancer Semin Oncol 18: 297
Pecorelli S, Bolis G, Vassena L, et al (1988) Randomized comparison of cisplatin and carboplatin in advanced ovarian cancer. Proc Am Soc Clin Oncol 7: 136
Perez RP, Perez KM, Handel LM, Hamilton TC (1992) In vitro interaction between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 29: 430
Rozencweig M, Nicaise C, Beer M et al (1983) Phase I study of carboplatin given on a 5 day intravenous schedule. J Clin Oncol 1: 621
Ten Bokkel Huinink WW, Dubbelman R, Aartsen E, Franklin H, McVie JG (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12: 43
Ten Bokkel Huinink WW, Burg MEL van der, Oosterom AT van, Neijt JP, George M, Guastalla JP, Veenhof CM, Rotmansz N, Dalesio O, Vermorken JB (1988) Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev 15: 9
Terheggen PMAB, Dijkman R, Begg AC, Dubbelman R, Floo BGJ, Hart AAM, Engelse L den (1988) Monitoring of interaction products ofcis-diamminedichloroplatinum(II) andcis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res 48: 5597
Terheggen PMAB, Begg AC, Emondt JY, Dubbelman R, Floot BGJ, Engelse L den (1991) Formation of interaction products of carboplatin with DNA in vitro and in cancer patients. Br J Cancer 63: 195
Echo DA van, Egorin MJ, Whitacre MY (1984) Phase I clinical and pharmacological trial of carboplatin daily for 5 days. Cancer Treat Rev 68: 1103
Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM (1979) Toxic side effects ofcis-diamminedichloroplatinum(II) in man. Cancer Treat Rep 63: 1527
Wiltshaw E (1985) Ovarian trials at the Royal Marsden. Cancer Treat Rev 12: 67–71
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Los, G., Tuyt, L., van Vugt, M. et al. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. Cancer Chemother. Pharmacol. 32, 425–433 (1993). https://doi.org/10.1007/BF00685885
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685885